LGI1 and encephalitis: The first group comprised 238 patients with anti-NMDAR encephalitis, while the second group consisted of 150 patients with anti-LGI1 or anti-CASPR2 encephalitis (anti-LGI1 107 patients, anti-CASPR2 43 patients).